STOCKHOLM, Aug. 21, 2024 /PRNewswire/ — RaySearch Laboratories AB (publ) is pleased to announce that the Connecticut Proton Therapy Center, Wallingford, Connecticut, USA, has placed an order for the oncology information system RayCare®*.
The Connecticut Proton Therapy Center will be the first of its kind in the state of Connecticut and is a collaboration between Yale New Haven Health, Hartford HealthCare and Proton International. The center has selected RayCare and the IBA Proteus®ONE compact proton therapy system as its treatment platform.
RayCare will be Connecticut Proton Therapy Center’s only oncology information system and will be utilized with the ProteusONE proton system. The center will use the workflow engine of RayCare for creating clinic specific workflows, with the aim of a complete clinical implementation in 2026, when the center opens. RayCare will also be used together with RaySearch’s treatment planning system RayStation, which was acquired in 2023.
Johan Löf, founder and CEO, RaySearch, says: “We are happy to welcome yet another RayCare customer. For our installed base of RayStation customers the selection of RayCare as oncology information system will enhance efficiency and user experience, both in the treatment planning process and treatment delivery.”
Revenue from the order is expected to be recognized during 2025.
For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
johan.lof@raysearchlabs.com
* Subject to regulatory clearance in some markets.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
|
RaySearch Press Release August 21, 2024 |
|
|
RayCare-Connecticut Proton Therapy Center 1200×620 |
SOURCE RaySearch Laboratories
Young Women Activists Launch "What Girls Want," Demand World Leaders Put Girls at the Center…
As a leader in neuroscience, Teva is committed to researching new treatment innovations that may…
As a leader in neuroscience, Teva remains committed to helping address unmet needs in the…
Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment…
MIAMI, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (OTC: SMFL) (“Smart for…
SAN FRANCISCO, Sept. 20, 2024 /PRNewswire/ -- The Global Ultrasound Institute (GUSI) is proud to…